New combo aims to extend control of tough pancreatic cancer
NCT ID NCT05249101
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the experimental drug ivaltinostat to standard chemotherapy (capecitabine) can help keep metastatic pancreatic cancer from worsening. About 70 adults whose cancer did not progress on initial treatment will receive either the combination or capecitabine alone. The goal is to find the best dose and see if the combination improves how long the cancer stays controlled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Clinical Research Alliance
Westbury, New York, 11590, United States
-
Community Health Network
Indianapolis, Indiana, 46250, United States
-
Hoag Medical Group
Newport Beach, California, 92663, United States
-
HonorHealth Research Institute
Scottsdale, Arizona, 85258, United States
-
Norton Cancer Institute Audubon
Louisville, Kentucky, 40217, United States
-
Penn State Hershey Cancer Institute
Hershey, Pennsylvania, 17033, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
The University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
-
UCLA Hematology/Oncology, Gastrointestinal Oncology
Santa Monica, California, 90404, United States
-
UCSF Medical Center
San Francisco, California, 94143, United States
-
University Cancer and Blood Center
Athens, Georgia, 30607, United States
-
University Medical Center New Orleans
New Orleans, Louisiana, 70112, United States
-
Utah Cancer Specialists
Salt Lake City, Utah, 84107, United States
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
- Can a targeted antibody give pancreatic cancer chemo a boost?
- Can High-Dose vitamin c boost chemo against pancreatic cancer?
- Could a nerve zap stop cancer wasting? early trial tests device for cachexia
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Experimental drug hopes to boost chemo against tough pancreatic cancer